Loading…
Dyne Therapeutics, Inc. is projected to rise to $31.60 by 2027, a +23% move from its current price of $25.73. DYN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $25.06 | $25.73 | $26.43 | +0.02% |
| Aug 2 | $24.79 | $25.74 | $26.72 | +0.03% |
| Aug 3 | $24.58 | $25.74 | $26.96 | +0.05% |
| Aug 4 | $24.41 | $25.75 | $27.15 | +0.07% |
| Aug 5 | $24.27 | $25.75 | $27.33 | +0.08% |
| Aug 6 | $24.13 | $25.76 | $27.49 | +0.10% |
| Aug 7 | $24.01 | $25.76 | $27.64 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.01 | $25.76 | $27.64 | +0.12% |
| Week 2 | $23.35 | $25.79 | $28.49 | +0.23% |
| Week 3 | $22.86 | $25.82 | $29.16 | +0.35% |
| Week 4 | $22.46 | $25.85 | $29.75 | +0.46% |
| Week 5 | $22.11 | $25.88 | $30.28 | +0.58% |
| Week 6 | $21.81 | $25.91 | $30.78 | +0.69% |
| Week 7 | $21.54 | $25.94 | $31.24 | +0.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dyne Therapeutics, Inc. is a healthcare company described as clinical-stage and focused on neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics with programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
The company operates in the healthcare space as a developer of therapeutics for neuromuscular diseases. Its work aims to advance multiple programs that target muscle-related disorders, leveraging its FORCE platform to deliver disease-modifying therapeutics. The description places the business squarely as a clinical-stage company centered on muscle disease therapies in the United States.
Dyne Therapeutics, Inc. (DYN) is a healthcare stock currently priced at $25.63 with a market cap of $4.24B, and it ranks 1415 by market capitalization.
The price outlook drawn from the provided forecast shows a path of rising averages in coming years, with 2026 avg listed as $25.63 and higher averages appearing in later years (e.g., 2030 avg $43.03, 2040 avg $136.41, 2050 avg $296.65). This suggests an upward trajectory in projected value over the longer term.
The forecast indicates a neutral stance for 2026 (min $14.60, avg $25.63, max $34.11; ROI 0; sentiment Neutral) followed by bullish sentiment and increasing average prices in subsequent years through 2050, signaling continued upside potential according to the stated estimates.
A major floor 38.1% below — a decisive break under it would weaken the trend.
The nearest floor, 25.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 17.8% above — clearing it would confirm fresh momentum.
Key DYN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DYN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.36 | Buy | $25.24 | Buy |
| MA 10 | $24.49 | Buy | $24.71 | Buy |
| MA 20 | $24.02 | Buy | $23.79 | Buy |
| MA 50 | $20.89 | Buy | $21.81 | Buy |
| MA 100 | $19.64 | Buy | $20.26 | Buy |
| MA 200 | $19.05 | Buy | $18.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.98 | Neutral |
| Stoch RSI (14) | 68.53 | Neutral |
| CCI (20) | 163.82 | Buy |
| Williams %R (14) | -5.35 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 8.20 | Buy |
| Bollinger %B (20,2) | 0.98 | Neutral |
| Stochastic %K (14) | 94.65 | Sell |
| TRIX (15) | 0.82 | Buy |
| Awesome (5,34) | 2.99 | Buy |
| Ultimate (7,14,28) | 68.07 | Neutral |
| Momentum (10) | 3.01 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 26.08 | Sell |
| ADX (14) | 27.68 | Buy |
| ATR (14) | 0.61 | Info |
The 30-day technical picture shows a bullish tilt. RSI(14) is 70, suggesting momentum toward the upside. The stock trades relative to its moving averages with the SMA50 at $20.28 and the SMA200 at $18.83.
Support is indicated at $17.95 and resistance at $25.63, framing a near-term trading setup. The 30-day trading range spans from $21.03 to $31.23, showing a broad window for price movement in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.60 | $25.73 | $34.04 | 0% | Neutral | |
| $25.26 | $31.60 | $41.76 | +23% | Bullish | |
| $29.55 | $38.00 | $52.08 | +48% | Bullish | |
| $29.76 | $39.14 | $55.21 | +52% | Bullish | |
| $33.50 | $44.95 | $64.93 | +75% | Bullish | |
| $42.26 | $57.73 | $85.17 | +124% | Bullish | |
| $48.16 | $66.90 | $100.56 | +160% | Bullish | |
| $54.94 | $77.53 | $118.53 | +201% | Bullish | |
| $56.23 | $80.55 | $125.10 | +213% | Bullish | |
| $55.91 | $81.24 | $128.01 | +216% | Bullish | |
| $93.34 | $144.72 | $242.29 | +462% | Bullish | |
| $182.24 | $315.72 | $577.51 | +11.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.60 | $25.73 | $30.02 | +0.00% |
| August 2026 | $22.02 | $25.83 | $30.99 | +0.39% |
| September 2026 | $22.09 | $26.12 | $31.75 | +1.12% |
| October 2026 | $22.83 | $27.18 | $33.38 | +4.05% |
| November 2026 | $23.01 | $27.53 | $34.10 | +1.29% |
| December 2026 | $22.68 | $27.28 | $34.04 | -0.92% |
Click any year to see its month-by-month DYN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The DYN price prediction for 2026 points to an average of $25.73 (low $14.60, high $34.04) — a potential gain of 0% on today's $25.73. Price action looks broadly range-bound.
In 2027, DYN is projected to trade between $25.26 and $41.76, averaging $31.60 — a potential gain of +23% from today's $25.73. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Dyne Therapeutics, Inc.'s 2028 outlook centres on $38.00, within a $29.55 to $52.08 range. That is up +20% on the projected 2027 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2029, DYN could reach as high as $55.21, with a base case around $39.14 and support toward $29.76 — roughly +52% from $25.73. Buyers look set to stay in control over this stretch.
Expect DYN to range from $33.50 to $64.93 through 2030. The $44.95 average target implies a +75% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The DYN price prediction for 2031 points to an average of $57.73 (low $42.26, high $85.17) — a potential gain of +124% on today's $25.73. Buyers look set to stay in control over this stretch.
In 2032, DYN is projected to trade between $48.16 and $100.56, averaging $66.90 — a potential gain of +160% from today's $25.73. That is up +16% on the projected 2031 average. Momentum favours further upside here.
Dyne Therapeutics, Inc.'s 2033 outlook centres on $77.53, within a $54.94 to $118.53 range. That is up +16% on the projected 2032 average. That marks a +201% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, DYN could reach as high as $125.10, with a base case around $80.55 and support toward $56.23 — roughly +213% from $25.73. Momentum favours further upside here.
Expect DYN to range from $55.91 to $128.01 through 2035. The $81.24 average target implies a +216% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The DYN price prediction for 2040 points to an average of $144.72 (low $93.34, high $242.29) — a potential gain of +462% on today's $25.73. Momentum favours further upside here.
In 2050, DYN is projected to trade between $182.24 and $577.51, averaging $315.72 — a potential gain of +11.3x from today's $25.73. That is up +118% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DYN today (≈ 38.865138 DYN) could be worth
$12,270.47
+$11,270.47 (+1127%) by 2050 · US Dollar
Based on the average projected DYN price of $315.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DYNwould be worth at today's price.
$1,000 invested in DYN on Jul 30, 2025 (≈ 100.908175 DYN) would be worth
$2,596.37
+$1,596.37 (+159.6%) today · 2.60× · US Dollar
Based on a DYN entry price of $9.91 vs. today's $25.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.89 | $1,077.02 | +7.7% |
| 1 month ago | $22.21 | $1,158.49 | +15.8% |
| 3 months ago | $17.39 | $1,479.59 | +48.0% |
| 6 months ago | $17.89 | $1,438.23 | +43.8% |
| 1 year ago | $9.91 | $2,596.37 | +159.6% |
| All time (5.0y) ago | $17.94 | $1,434.23 | +43.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DYN forecast.
Our base-case forecast reaches $51.00 around 2031.
Implied market cap at $51.00: $9.52B
The multi-year forecast paints a clear long-run upside path, with the average price rising across multiple years and bullish sentiment persisting through 2050. In 2030, the avg is $43.03 with a max of $63.76 and a min of $31.38, yielding a 67.9% ROI and bullish sentiment. The 2040 forecast shows a much higher avg of $136.41, with a max of $237.47 and a min of $84.02, delivering a 432.3% ROI and bullish sentiment.
By 2050, the avg is $296.65, the min is $160.01, and the max is $568.29, for a 1057.4% ROI and bullish sentiment.
Across years 2027 through 2035, the avg prices rise from $31.23 (2027) to $76.28 (2035) with increasingly large max values and double-digit to triple-digit ROI figures, all tagged as bullish. These are estimates and not guarantees, and the forecast explicitly labels sentiment as BULLISH for these later years while acknowledging inherent uncertainty in future price directions.
Tap a question to reveal the answer.
In 2030 the forecast lists a min of $31.38, a avg of $43.03, and a max of $63.76 with an ROI of 67.9% and sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising average prices and notable ROIs (e.g., 21.9% in 2027, up to 1057.4% by 2050). These are estimates and not guarantees.
Yes. The forecast for 2032 lists a max of $100.01, and 2033 lists a max of $118.37, suggesting a path above $100 in those years.
Current price is $25.63. The 30-day range is from $21.03 to $31.23.
For 2040, the avg price is $136.41 with a max of $237.47, min $84.02, ROI 432.3%, sentiment BULLISH. For 2050, the avg price is $296.65 with a max of $568.29, min $160.01, ROI 1057.4%, sentiment BULLISH.
Dyne Therapeutics, Inc. Community Discussion
0Share your Dyne Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.